OMO-103

DRUG3 trials

Sponsors

Peptomyc S.L., Vall d'Hebron Institute of Oncology

Conditions

Advanced Solid TumorsCRCMetastatic Pancreatic CancerOsteosarcomaOsteosarcoma in ChildrenPancreatic Cancer

Phase 1

Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours

TerminatedNCT04808362

Peptomyc S.L.Advanced Solid Tumors, CRC, Pancreatic Cancer

Start: 2021-04-28End: 2023-01-11Updated: 2024-04-25

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

Active, not recruitingNCT06059001

Peptomyc S.L.Metastatic Pancreatic Cancer

Start: 2023-08-31End: 2026-05-31Updated: 2026-01-14

Phase 2

A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

RecruitingNCT06650514

Vall d'Hebron Institute of OncologyOsteosarcoma, Osteosarcoma in Children

Start: 2024-12-27End: 2026-12-31Target: 10Updated: 2025-01-10

Related Papers

Abstract 7174: Restoring antitumor immunity and improving immunotherapy outcomes in KRAS-mutant NSCLC through MYC inhibition by OMO-103

Cancer Research2026-04-03

Pharmacokinetic analysis of OMO-103 in patient tissues with advanced solid tumors.

Journal of Clinical Oncology2024-06-01

Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties

ACS Omega2024-05-033 citations

Abstract 7166: Pharmacokinetic analysis of omomyc therapeutic protein in preclinical and human tumor tissue using targeted mass spectrometry

Cancer Research2024-03-22

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Nature Medicine2024-02-06136 citations